WEBULL
News
FBRX
19.93
-3.06%
-0.63
Weekly Report: what happened at FBRX last week (1124-1128)?
Weekly Report · 5d ago
Forte Biosciences Initiated at Outperform by Evercore ISI Group
Dow Jones · 11/25 13:07
Forte Biosciences Price Target Announced at $65.00/Share by Evercore ISI Group
Dow Jones · 11/25 13:07
Evercore ISI Group Initiates Coverage On Forte Biosciences with Outperform Rating, Announces Price Target of $65
Benzinga · 11/25 12:56
Forte Biosciences initiated with an Outperform at Evercore ISI
TipRanks · 11/25 11:35
Forte Biosciences Grants Equity Inducement Award to New Employee
Reuters · 11/24 21:01
FORTE BIOSCIENCES, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULES
Reuters · 11/24 21:01
Weekly Report: what happened at FBRX last week (1117-1121)?
Weekly Report · 11/24 10:39
Forte Biosciences Price Target Maintained With a $61.00/Share by Chardan Capital
Dow Jones · 11/17 13:00
Forte Biosciences Is Maintained at Buy by Chardan Capital
Dow Jones · 11/17 13:00
Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target
Benzinga · 11/17 12:50
Weekly Report: what happened at FBRX last week (1110-1114)?
Weekly Report · 11/17 10:40
Forte Biosciences Reports Increased R&D Costs Amid Clinical Progress
TipRanks · 11/15 04:08
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Forte Biosciences (FBRX)
TipRanks · 11/14 19:30
Forte Biosciences GAAP EPS of -$0.99 beats by $0.04
Seeking Alpha · 11/14 18:41
Forte Biosciences Q3 net loss per share improves
Reuters · 11/14 14:09
Forte Biosciences reports Q3 EPS (99c), consensus ($1.07)
TipRanks · 11/14 14:05
Forte Biosciences posts Q3 net loss of $17.7 million
Reuters · 11/14 14:00
FORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2025 RESULTS AND PROVIDES UPDATE
Reuters · 11/14 14:00
FORTE BIOSCIENCES Q3 BASIC EPS USD -0.99
Reuters · 11/14 14:00
More
Webull provides a variety of real-time FBRX stock news. You can receive the latest news about Forte Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBRX
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.